View ValuationJEOL 将来の成長Future 基準チェック /26JEOL利益と収益がそれぞれ年間17.7%と0.3%増加すると予測されています。EPS は年間 増加すると予想されています。自己資本利益率は 3 年後に14.7% 18.2%なると予測されています。主要情報17.7%収益成長率18.20%EPS成長率Electronic 収益成長39.2%収益成長率0.3%将来の株主資本利益率14.71%アナリストカバレッジGood最終更新日16 Apr 2026今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesお知らせ • Feb 02JEOL Ltd. (TSE:6951) announces an Equity Buyback for 2,500,000 shares, representing 4.88% for ¥12,870 million.JEOL Ltd. (TSE:6951) announces a share repurchase program. Under the program, the company will repurchase up to 2,500,000 shares, representing 4.88% of its issued share capital, for ¥12,870 million. Shares will be repurchased at a price of ¥5,148 per share. Under the offer the company will repurchase 2,300,000 shares from Nikon Corporation. The purpose of the program is returning profits to shareholders and to enable the agile implementation of capital policies in response to changes in the business environment. If the number of tendered shares exceed the number of shares to be purchased then the actual number of shares purchased may exceed the number of shares to be purchased as a result of unit adjustment on a pro rata basis. The offer is valid till March 4, 2026. As of September 30, 2025, the company had 51,181,974 shares (excluding treasury shares) and 350,826 shares in treasury.お知らせ • Dec 06JEOL Ltd. to Report Q3, 2026 Results on Feb 13, 2026JEOL Ltd. announced that they will report Q3, 2026 results on Feb 13, 2026お知らせ • Sep 26JEOL Ltd. to Report Q2, 2026 Results on Nov 14, 2025JEOL Ltd. announced that they will report Q2, 2026 results on Nov 14, 2025お知らせ • Jun 27JEOL Ltd. to Report Q1, 2026 Results on Aug 13, 2025JEOL Ltd. announced that they will report Q1, 2026 results on Aug 13, 2025お知らせ • May 15JEOL Ltd., Annual General Meeting, Jun 26, 2025JEOL Ltd., Annual General Meeting, Jun 26, 2025.お知らせ • Mar 15JEOL Ltd. to Report Fiscal Year 2025 Results on May 15, 2025JEOL Ltd. announced that they will report fiscal year 2025 results on May 15, 2025お知らせ • Dec 04JEOL Ltd. to Report Q3, 2025 Results on Feb 12, 2025JEOL Ltd. announced that they will report Q3, 2025 results on Feb 12, 2025お知らせ • Nov 26JEOL Ltd. (TSE:6951) agreed to acquire an additional majority stake in Japan Superconductor Technology, Inc. from Kobe Steel, Ltd. (TSE:5406).JEOL Ltd. (TSE:6951) agreed to acquire an additional majority stake in Japan Superconductor Technology, Inc. from Kobe Steel, Ltd. (TSE:5406) on November 22, 2024. Post the closing of the transaction, Kobe Steel will not hold any stake in Japan Superconductor Technology. For the period ending March 31, 2024, Japan Superconductor Technology, Inc. reported total revenue of ¥4.14 billion. The expected completion of the transaction is January 6, 2025.Reported Earnings • Nov 10Second quarter 2025 earnings released: EPS: JP¥137 (vs JP¥113 in 2Q 2024)Second quarter 2025 results: EPS: JP¥137 (up from JP¥113 in 2Q 2024). Revenue: JP¥50.9b (up 27% from 2Q 2024). Net income: JP¥7.02b (up 21% from 2Q 2024). Profit margin: 14% (in line with 2Q 2024). Revenue is forecast to grow 4.0% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Electronic industry in Germany. Over the last 3 years on average, earnings per share has increased by 30% per year but the company’s share price has fallen by 20% per year, which means it is significantly lagging earnings.Buy Or Sell Opportunity • Nov 09Now 21% overvalued after recent price riseOver the last 90 days, the stock has risen 11% to €36.40. The fair value is estimated to be €30.06, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 15% over the last 3 years. Earnings per share has grown by 35%. Revenue is forecast to grow by 13% in 2 years. Earnings are forecast to grow by 24% in the next 2 years.Buy Or Sell Opportunity • Oct 15Now 20% overvaluedOver the last 90 days, the stock has fallen 9.4% to €36.80. The fair value is estimated to be €30.65, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 15% over the last 3 years. Earnings per share has grown by 35%. Revenue is forecast to grow by 13% in 2 years. Earnings are forecast to grow by 24% in the next 2 years.お知らせ • Sep 27JEOL Ltd. to Report Q2, 2025 Results on Nov 08, 2024JEOL Ltd. announced that they will report Q2, 2025 results on Nov 08, 2024Upcoming Dividend • Sep 20Upcoming dividend of JP¥44.00 per shareEligible shareholders must have bought the stock before 27 September 2024. Payment date: 11 December 2024. Payout ratio is a comfortable 18% and this is well supported by cash flows. Trailing yield: 1.7%. Lower than top quartile of German dividend payers (4.8%). In line with average of industry peers (1.8%).お知らせ • Sep 04JEOL Ltd. Announces the Release of the New CROSS SECTION POLISHER IB-19540CP / COOLING CROSS SECTION POLISHER IB-19550CCP for Electron MicroscopesJEOL Ltd. announced the release of the New CROSS SECTION POLISHER IB-19540CP /COOLING CROSS SECTION POLISHER IB-19550CCP for Electron Microscopes on September 4, 2024. CROSS SECTION POLISHER™(CP)is widely utilized in the fields of electronic parts, ceramics, life science, metal, battery, and polymer. The mechanical high-quality uniform cross section can be easily prepared for complex materials and fragile specimens. With a sales record of over 2,000 units since its launch in 2003, the CP has been an essential tool for pre-treatment. The IB-19540CP /IB-19550CCP have been advanced with enhanced user-friendliness. Incorporation of the new GUI and IoT (Internet of Things) further improves ease of use and enables remote control and milling process monitoring by PC. High throughput ion source and high throughput cooling system enable preparation of a smooth cross section rapidly with less damages. Main features: New GUI and Internet of Things (IoT) - Incorporation of a new GUI makes the operation steps easy to understand. Easy setup is possible by following the flowchart on the control panel. Preset functions are available for saving and recalling process conditions tailored to specific applications or specimen types. Connecting to LAN provides remote access and control through a web browser to the CP. Monitoring and adjusting the milling process over multiple CPs is possible. High throughput ion source: High throughput ion source is equipped as a standard. The ion current density has been improved by optimizing the ion-source electrode and increasing the accelerating voltage. The standard cross section milling rate is now 1,200 µm/h and it will help reduce the time required for processing. Milling of 1 h, Si equivalent, Edge distance: 100 µm. High throughput cooling system: The high throughput cooling system and the new GUI enable automatic operation from cooling to return to room temperature. Thus, the waiting time has been reduced and it helps shorten the time required for work. It is possible to vacuum around the liquid nitrogen tank from the CP side to maintain cooling retention time and specimen cooling temperature. Annual Unit Sales Target - 180 units/year.Valuation Update With 7 Day Price Move • Aug 22Investor sentiment improves as stock rises 15%After last week's 15% share price gain to €39.20, the stock trades at a forward P/E ratio of 13x. Average forward P/E is 15x in the Electronic industry in Germany. Total loss to shareholders of 31% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €30.89 per share.Reported Earnings • Aug 18First quarter 2025 earnings released: EPS: JP¥76.26 (vs JP¥33.76 in 1Q 2024)First quarter 2025 results: EPS: JP¥76.26 (up from JP¥33.76 in 1Q 2024). Revenue: JP¥36.4b (up 27% from 1Q 2024). Net income: JP¥3.90b (up 126% from 1Q 2024). Profit margin: 11% (up from 6.0% in 1Q 2024). The increase in margin was driven by higher revenue. Revenue is forecast to grow 5.9% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Electronic industry in Germany. Over the last 3 years on average, earnings per share has increased by 35% per year but the company’s share price has fallen by 11% per year, which means it is significantly lagging earnings.Buy Or Sell Opportunity • Aug 18Now 24% overvaluedOver the last 90 days, the stock has fallen 2.1% to €37.80. The fair value is estimated to be €30.58, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 15% over the last 3 years. Earnings per share has grown by 35%. Revenue is forecast to grow by 12% in 2 years. Earnings are forecast to grow by 23% in the next 2 years.New Risk • Aug 05New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 7.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company.Valuation Update With 7 Day Price Move • Aug 05Investor sentiment deteriorates as stock falls 18%After last week's 18% share price decline to €28.80, the stock trades at a forward P/E ratio of 9x. Average forward P/E is 15x in the Electronic industry in Germany. Total loss to shareholders of 50% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €11.70 per share.お知らせ • Jul 31JEOL Ltd. Announces New Schottky Field Emission Scanning Electron Microscope JSM-IT810 ReleasedJEOL Ltd. announced the release of the new Schottky Field Emission Scanning Electron Microscope JSM-IT810 on July 28, 2024. Field Emission Scanning Electron Microscopes (FESEM) are widely used in science and technology fields such as research institutes, universities, and industry. There is a growing demand for an instrument that can be used easily, accurately, quickly, and efficiently from observation to analysis. The JSM-IT810 adds the "Neo Action" automatic observation and analysis function and automatic calibration function to the JSM-IT800, which is equipped with the next-generation electron optical control system “Neo Engine” and the “SEM Center” for high operability such as Zeromag and EDS integration, to not only improve efficiency and productivity but also help solve labor shortages. Main Features: 1. Automatic Observation and Analysis Function “Neo Action”: All you need to do is select the SEM image acquisition conditions and field of view, and the function automatically performs SEM observation and EDS (energy dispersive X-ray spectroscopy) analysis. This function contributes to improving the efficiency of routine work including analysis work. 2. Automatic Calibration Function “SEM Automatic Adjustment Package”: This function enables automatic execution of the selected items in alignment adjustment, magnification adjustment, and EDS energy calibration. 3. “Live Function”: This function is capable of Live 3D, Live Analysis, and Live Map functions. 3D images can be constructed on the spot while an SEM observation is being performed to obtain unevenness and depth information. In addition, it helps always display characteristic X-ray spectrum and elemental mapping. 4. EDS Integration: Observation by an SEM and analysis by an EDS are integrated. Analysis of point, area, and MAP can be performed from the observation screen. Incorporation of the Windowless EDS-Gather-X enables detection from Li and analysis at a high sensitivity and high spatial resolution.お知らせ • May 30JEOL Ltd. Announces the Release of the New Electron Microscope JEM-120iJEOL Ltd. announced the release of the new electron microscope JEM-120i developed with the concepts of “Compact”, “Easy To Use”, and “Expandable” on May 30, 2024. Electron microscopes are utilized in a wide range of fields from biotechnology to nano technology, polymers, and advanced materials. With the expansion of application, usages are also expanding, which requires a tool that is easy-to-use for research and testing purposes. To satisfy such needs, the JEM-120i has evolved into a next-generation microscope that is easy to use, from operation to maintenance, for both beginner and experienced users. Compact: The JEM-120i adopts a totally new appearance and compact design that fits any installation location. The footprint has been reduced by more than 50%, and the volume occupied by the instrument is less than one-third of that of conventional models, enabling effective use of space. The instrument height is lower than 1,800mm, which fits just about any installation room. Easy to Use: The enhanced TEM control system and fully automated apertures eliminated the need for switching the magnification mode and selecting an aperture. The JEM-120i provides seamless observations from low to high magnification. It takes only 4 steps from loading a specimen to completing an observation. After inserting the specimen holder, clicking the Start Button automatically performs observation preparation operations such as voltage increase and emission start. A wide area image is captured at the same time, and clicking the target field of view will complete the stage movement. Standard “Butler mode” assists data acquisition. Even a beginner can capture data easily. Expandable: In addition to the standard multi-function camera, a bottom-mount camera of higher pixel count can be selected as an option. Attachments such as the scanning image observation function (STEM), elemental analysis function (EDS), and cryo observation function can be applied, regardless of instrument configuration. The instrument can be expanded at any time to meet the changing needs of microscopy over time. The proven scripting function (PyJEM) with the high-end models, can create an algorithm for automation. The automation can increase the utilization rate of the instrument and improve data output efficiency. Main Specifications: Resolution- 0.2 nm (HC), 0.14 nm (HR). Accelerating voltage- 20-120kV. Magnification- 50-1,200,000 (HC), 50-1,500,000 (HR). Standard camera- JEOL CMOS camera (NeoView) 4M pixel, 30fps. Field of view search/adjustment/recording. Optional camera- JEOL CMOS camera (SightSKY) 19M pixel, 58fps. Cameras made by other companies can also be mounted. Main unit dimensions: W 840mm/D 1,734mm/H 1,782mm.Reported Earnings • May 19Full year 2024 earnings released: EPS: JP¥425 (vs JP¥349 in FY 2023)Full year 2024 results: EPS: JP¥425 (up from JP¥349 in FY 2023). Revenue: JP¥174.3b (up 7.2% from FY 2023). Net income: JP¥21.7b (up 22% from FY 2023). Profit margin: 12% (up from 11% in FY 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 7.6% p.a. on average during the next 3 years, compared to a 6.9% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 40% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings.お知らせ • May 16JEOL Ltd., Annual General Meeting, Jun 26, 2024JEOL Ltd., Annual General Meeting, Jun 26, 2024.お知らせ • May 15JEOL Ltd. Announces Resignation of Gon-Emon Kurihara as ChairmanJEOL Ltd. announced the resignation of Gon-emon Kurihara as chairman of the company due to expiration of term.Upcoming Dividend • Mar 21Upcoming dividend of JP¥41.00 per shareEligible shareholders must have bought the stock before 28 March 2024. Payment date: 01 July 2024. Payout ratio is a comfortable 24% but the company is not cash flow positive. Trailing yield: 1.2%. Lower than top quartile of German dividend payers (5.0%). Lower than average of industry peers (1.6%).お知らせ • Mar 02JEOL Ltd. to Report Fiscal Year 2024 Results on May 14, 2024JEOL Ltd. announced that they will report fiscal year 2024 results on May 14, 2024Reported Earnings • Feb 11Third quarter 2024 earnings released: EPS: JP¥51.48 (vs JP¥118 in 3Q 2023)Third quarter 2024 results: EPS: JP¥51.48 (down from JP¥118 in 3Q 2023). Revenue: JP¥38.2b (down 11% from 3Q 2023). Net income: JP¥2.63b (down 56% from 3Q 2023). Profit margin: 6.9% (down from 14% in 3Q 2023). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 7.2% p.a. on average during the next 3 years, compared to a 6.5% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 43% per year but the company’s share price has only increased by 4% per year, which means it is significantly lagging earnings growth.Buy Or Sell Opportunity • Jan 31Now 20% undervaluedOver the last 90 days, the stock has risen 43% to €42.80. The fair value is estimated to be €53.72, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 16% over the last 3 years. Earnings per share has grown by 48%. Revenue is forecast to grow by 12% in 2 years. Earnings are forecast to grow by 23% in the next 2 years.Valuation Update With 7 Day Price Move • Jan 26Investor sentiment improves as stock rises 21%After last week's 21% share price gain to €45.40, the stock trades at a forward P/E ratio of 19x. Average forward P/E is 25x in the Medical Equipment industry in Germany. Total returns to shareholders of 35% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €53.32 per share.お知らせ • Nov 27JEOL Ltd. to Report Q3, 2024 Results on Feb 09, 2024JEOL Ltd. announced that they will report Q3, 2024 results on Feb 09, 2024New Risk • Nov 14New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 6.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company.Reported Earnings • Nov 12Second quarter 2024 earnings released: EPS: JP¥113 (vs JP¥78.63 in 2Q 2023)Second quarter 2024 results: EPS: JP¥113 (up from JP¥78.63 in 2Q 2023). Revenue: JP¥40.0b (up 12% from 2Q 2023). Net income: JP¥5.79b (up 44% from 2Q 2023). Profit margin: 14% (up from 11% in 2Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 5.0% p.a. on average during the next 3 years, compared to a 6.1% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 48% per year but the company’s share price has only increased by 2% per year, which means it is significantly lagging earnings growth.Valuation Update With 7 Day Price Move • Nov 07Investor sentiment improves as stock rises 17%After last week's 17% share price gain to €31.00, the stock trades at a forward P/E ratio of 15x. Average forward P/E is 24x in the Medical Equipment industry in Germany. Total returns to shareholders of 10% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €48.84 per share.Upcoming Dividend • Sep 21Upcoming dividend of JP¥33.00 per share at 1.4% yieldEligible shareholders must have bought the stock before 28 September 2023. Payment date: 12 December 2023. Payout ratio is a comfortable 21% but the company is not cash flow positive. Trailing yield: 1.4%. Lower than top quartile of German dividend payers (4.8%). Lower than average of industry peers (2.0%).お知らせ • Aug 31JEOL Ltd. to Report Q2, 2024 Results on Nov 10, 2023JEOL Ltd. announced that they will report Q2, 2024 results on Nov 10, 2023Reported Earnings • Aug 13First quarter 2024 earnings released: EPS: JP¥33.76 (vs JP¥63.03 in 1Q 2023)First quarter 2024 results: EPS: JP¥33.76 (down from JP¥63.03 in 1Q 2023). Revenue: JP¥28.7b (flat on 1Q 2023). Net income: JP¥1.72b (down 46% from 1Q 2023). Profit margin: 6.0% (down from 11% in 1Q 2023). Revenue is forecast to grow 3.7% p.a. on average during the next 3 years, compared to a 6.3% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 47% per year but the company’s share price has only increased by 3% per year, which means it is significantly lagging earnings growth.お知らせ • Jun 03JEOL Ltd. to Report Q1, 2024 Results on Aug 10, 2023JEOL Ltd. announced that they will report Q1, 2024 results on Aug 10, 2023Reported Earnings • May 16Full year 2023 earnings released: EPS: JP¥349 (vs JP¥247 in FY 2022)Full year 2023 results: EPS: JP¥349 (up from JP¥247 in FY 2022). Revenue: JP¥162.7b (up 18% from FY 2022). Net income: JP¥17.8b (up 45% from FY 2022). Profit margin: 11% (up from 8.9% in FY 2022). The increase in margin was driven by higher revenue. Revenue is forecast to grow 3.3% p.a. on average during the next 3 years, compared to a 6.4% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 49% per year but the company’s share price has remained flat, which means it is significantly lagging earnings.お知らせ • May 14JEOL Ltd., Annual General Meeting, Jun 28, 2023JEOL Ltd., Annual General Meeting, Jun 28, 2023.Upcoming Dividend • Mar 23Upcoming dividend of JP¥30.00 per share at 1.6% yieldEligible shareholders must have bought the stock before 30 March 2023. Payment date: 29 June 2023. Payout ratio is a comfortable 18% and this is well supported by cash flows. Trailing yield: 1.6%. Lower than top quartile of German dividend payers (4.7%). In line with average of industry peers (1.7%).Reported Earnings • Feb 13Third quarter 2023 earnings released: EPS: JP¥118 (vs JP¥71.86 in 3Q 2022)Third quarter 2023 results: EPS: JP¥118 (up from JP¥71.86 in 3Q 2022). Revenue: JP¥43.0b (up 15% from 3Q 2022). Net income: JP¥6.04b (up 65% from 3Q 2022). Profit margin: 14% (up from 9.8% in 3Q 2022). The increase in margin was driven by higher revenue. Revenue is forecast to grow 4.3% p.a. on average during the next 3 years, compared to a 6.3% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 44% per year but the company’s share price has fallen by 2% per year, which means it is significantly lagging earnings.お知らせ • Feb 01JEOL Ltd. Announces its Launch of the FIB-SEM system “JIB-PS500i”JEOL Ltd. announced its launch of the FIB-SEM system “JIB-PS500i” on February 1, 2023. With the finer structure of advanced materials and advancing complexity of processes, evaluation techniques such as morphological observation and elemental analysis require higher resolution and precision. In the preparation of samples for transmission electron microscopes (TEM) in the semiconductor industry as well as in the battery and materials fields, "higher precision" and "thinner sample" are required. This product is a combined system of the FIB (Focused Ion Beam) system that can process with high accuracy and the SEM (scanning electron microscope) of high resolution to satisfy these needs. Main Features: The FIB column enables processing with a large-current Ga ion beam up to 100nA. The high-current processing is particularly effective in preparing cross section samples for large-area imaging and analysis. In addition, the FIB column is set to a shorter working distance. Along with a newly-developed power supply, it has led to greatly improved processing performance at a low accelerating voltage. A newly-developed super conical lens system is built into the SEM column, greatly improving the image resolution at a low accelerating voltage. This superb imaging is very useful to check the end-point milling status of lamella specimen using the SEM. The JIB-PS500i adopts a large specimen chamber and a newly-developed specimen stage, increasing the stage movement range, and thus accommodating a large specimen. In addition, a newly-developed STEM detector that can be used with the stage tilt at 90 degrees, allows for a seamless transition from the TEM specimen preparation to STEM observation. For the operating GUI, the “SEM center”, which has been well received in the JSM-IT800 series of high-resolution scanning electron microscopes is employed, enabling full integration of EDS analysis. A double tilt cartridge and a dedicated TEM holder allows for more precise alignment while making specimen transfer between TEM and FIB easier.Reported Earnings • Nov 16Second quarter 2023 earnings released: EPS: JP¥78.63 (vs JP¥59.59 in 2Q 2022)Second quarter 2023 results: EPS: JP¥78.63 (up from JP¥59.59 in 2Q 2022). Revenue: JP¥35.9b (up 21% from 2Q 2022). Net income: JP¥4.01b (up 38% from 2Q 2022). Profit margin: 11% (up from 9.8% in 2Q 2022). The increase in margin was driven by higher revenue. Revenue is forecast to grow 5.2% p.a. on average during the next 3 years, compared to a 6.2% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 36% per year but the company’s share price has only increased by 14% per year, which means it is significantly lagging earnings growth.Board Change • Nov 16Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, 1 was an independent director. The company's board is composed of: 2 independent directors. 6 non-independent directors. Independent Outside Director Ryuji Kanno was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity.Reported Earnings • Nov 13Second quarter 2023 earnings released: EPS: JP¥78.63 (vs JP¥59.59 in 2Q 2022)Second quarter 2023 results: EPS: JP¥78.63 (up from JP¥59.59 in 2Q 2022). Revenue: JP¥35.9b (up 21% from 2Q 2022). Net income: JP¥4.01b (up 38% from 2Q 2022). Profit margin: 11% (up from 9.8% in 2Q 2022). The increase in margin was driven by higher revenue. Revenue is forecast to grow 6.0% p.a. on average during the next 3 years, compared to a 6.3% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 36% per year but the company’s share price has only increased by 18% per year, which means it is significantly lagging earnings growth.Upcoming Dividend • Sep 22Upcoming dividend of JP¥30.00 per shareEligible shareholders must have bought the stock before 29 September 2022. Payment date: 06 December 2022. Payout ratio is a comfortable 17% and this is well supported by cash flows. Trailing yield: 1.1%. Lower than top quartile of German dividend payers (5.1%). Lower than average of industry peers (1.8%).お知らせ • Sep 14+ 1 more updateJEOL Ltd. to Report Q2, 2023 Results on Nov 11, 2022JEOL Ltd. announced that they will report Q2, 2023 results on Nov 11, 2022Reported Earnings • Aug 14First quarter 2023 earnings released: EPS: JP¥63.02 (vs JP¥15.79 in 1Q 2022)First quarter 2023 results: EPS: JP¥63.02 (up from JP¥15.79 in 1Q 2022). Revenue: JP¥28.9b (up 21% from 1Q 2022). Net income: JP¥3.22b (up 321% from 1Q 2022). Profit margin: 11% (up from 3.2% in 1Q 2022). The increase in margin was driven by higher revenue. Over the next year, revenue is forecast to grow 14%, compared to a 7.5% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 28% per year whereas the company’s share price has increased by 32% per year.お知らせ • Jun 23JEOL Ltd. to Report Q1, 2023 Results on Aug 12, 2022JEOL Ltd. announced that they will report Q1, 2023 results on Aug 12, 2022Reported Earnings • May 17Full year 2022 earnings released: EPS: JP¥247 (vs JP¥77.51 in FY 2021)Full year 2022 results: EPS: JP¥247 (up from JP¥77.51 in FY 2021). Revenue: JP¥138.4b (up 25% from FY 2021). Net income: JP¥12.3b (up 228% from FY 2021). Profit margin: 8.9% (up from 3.4% in FY 2021). The increase in margin was driven by higher revenue. Over the next year, revenue is forecast to grow 11%, compared to a 7.1% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has increased by 36% per year, which means it is tracking significantly ahead of earnings growth.お知らせ • May 15JEOL Ltd., Annual General Meeting, Jun 28, 2022JEOL Ltd., Annual General Meeting, Jun 28, 2022.Board Change • Apr 27Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 7 non-independent directors. Independent Outside Director Ryuji Kanno was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Apr 08JEOL Ltd. to Report Fiscal Year 2022 Results on May 13, 2022JEOL Ltd. announced that they will report fiscal year 2022 results on May 13, 2022Buying Opportunity • Mar 29Now 22% undervalued after recent price dropOver the last 90 days, the stock is down 32%. The fair value is estimated to be JP¥61.26, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Earnings per share has been flat over the last 3 years.Upcoming Dividend • Mar 23Upcoming dividend of JP¥14.00 per shareEligible shareholders must have bought the stock before 30 March 2022. Payment date: 28 June 2022. Payout ratio is a comfortable 21% and this is well supported by cash flows. Trailing yield: 0.4%. Lower than top quartile of German dividend payers (3.6%). Lower than average of industry peers (1.1%).Valuation Update With 7 Day Price Move • Mar 22Investor sentiment improved over the past weekAfter last week's 17% share price gain to €49.00, the stock trades at a forward P/E ratio of 24x. Average forward P/E is 34x in the Medical Equipment industry in Germany. Total returns to shareholders of 222% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €65.72 per share.Reported Earnings • Feb 06Third quarter 2022 earnings: EPS in line with analyst expectations despite revenue beatThird quarter 2022 results: EPS: JP¥71.85 (up from JP¥7.55 in 3Q 2021). Revenue: JP¥37.4b (up 45% from 3Q 2021). Net income: JP¥3.67b (up JP¥3.30b from 3Q 2021). Profit margin: 9.8% (up from 1.4% in 3Q 2021). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 8.0%. Over the next year, revenue is forecast to grow 15%, compared to a 12% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has remained flat but the company’s share price has increased by 47% per year, which means it is well ahead of earnings.Buying Opportunity • Jan 22Now 22% undervalued after recent price dropOver the last 90 days, the stock is down 23%. The fair value is estimated to be JP¥62.70, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Earnings per share has declined by 10% per annum over the last 3 years.Valuation Update With 7 Day Price Move • Jan 10Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to €59.50, the stock trades at a forward P/E ratio of 37x. Average forward P/E is 36x in the Medical Equipment industry in Germany. Total returns to shareholders of 344% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €61.71 per share.Reported Earnings • Nov 06Second quarter 2022 earnings released: EPS JP¥59.58 (vs JP¥37.61 in 2Q 2021)The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2022 results: Revenue: JP¥29.6b (up 4.0% from 2Q 2021). Net income: JP¥2.90b (up 60% from 2Q 2021). Profit margin: 9.8% (up from 6.4% in 2Q 2021). Over the last 3 years on average, earnings per share has fallen by 10% per year but the company’s share price has increased by 66% per year, which means it is well ahead of earnings.Upcoming Dividend • Sep 22Upcoming dividend of JP¥14.00 per shareEligible shareholders must have bought the stock before 29 September 2021. Payment date: 04 December 2021. Trailing yield: 0.3%. Lower than top quartile of German dividend payers (3.2%). Lower than average of industry peers (0.8%).Valuation Update With 7 Day Price Move • Jun 04Investor sentiment improved over the past weekAfter last week's 16% share price gain to JP¥45.80, the stock trades at a forward P/E ratio of 41x. Average forward P/E is 47x in the Medical Equipment industry in Germany. Total returns to shareholders of 162% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €38.38 per share.Reported Earnings • May 17Full year 2021 earnings released: EPS JP¥77.51 (vs JP¥111 in FY 2020)The company reported a poor full year result with weaker earnings, revenues and profit margins. Full year 2021 results: Revenue: JP¥110.4b (down 5.8% from FY 2020). Net income: JP¥3.75b (down 30% from FY 2020). Profit margin: 3.4% (down from 4.6% in FY 2020). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has fallen by 5% per year but the company’s share price has increased by 29% per year, which means it is well ahead of earnings.Valuation Update With 7 Day Price Move • Apr 17Investor sentiment improved over the past weekAfter last week's 31% share price gain to JP¥45.20, the stock trades at a forward P/E ratio of 43x. Average forward P/E is 50x in the Medical Equipment industry in Germany. Total returns to shareholders of 238% over the past three years.Upcoming Dividend • Mar 24Upcoming dividend of JP¥12.00 per shareEligible shareholders must have bought the stock before 30 March 2021. Payment date: 26 June 2021. Trailing yield: 0.6%. Lower than top quartile of German dividend payers (3.3%). Lower than average of industry peers (1.0%).Is New 90 Day High Low • Feb 25New 90-day low: €31.00The company is down 9.0% from its price of €34.20 on 26 November 2020. The German market is up 7.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is up 21% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €36.38 per share.お知らせ • Feb 18JEOL Ltd. Releases JMS-T2000GC AccuTOF(TM) GC-AlphaJEOL Ltd. announced the release of JMS-T2000GC AccuTOF(TM) GC-Alpha, the latest model of the successful AccuTOF(TM) GC series gas chromatograph – time-of-flight mass spectrometers, to be released in February 2021. This product is a GC-MS that represents a significant improvement in performance and functionality using two newly developed Key Technologies. The basic hardware performance has been greatly improved and a new generation of automated data analysis software is included in the standard configuration. The JMS-T2000GC AccuTOF(TM) GC-Alpha, the 6th generation of the successful AccuTOF(TM) GC series, achieves three times the mass resolving power and mass measurement accuracy of the previous AccuTOF(TM) GCx-plus by using a whole new ion optics design that achieves excellent sensitivity and high data acquisition speed, the long-time hallmarks for the AccuTOF(TM) GC series. Additionally, the system has a wide dynamic range that is beneficial not only for quantitative analysis but also for qualitative analysis of complex mixtures. A wide variety of ionization techniques – field ionization (FI), field desorption (FD), photoionization (PI), and chemical ionization (CI) – are optionally available, in addition to the standard electron ionization (EI). Two combination ion sources are also available as options – the EI/FI/FD combination ion source and the EI/PI combination ion source which allow easy switching between ionization techniques without breaking vacuum or replacing the ion sources.Analyst Estimate Surprise Post Earnings • Feb 07Revenue misses expectationsRevenue missed analyst estimates by 7.7%. Over the next year, revenue is forecast to grow 8.0%, compared to a 14% growth forecast for the Medical Equipment industry in Germany.Reported Earnings • Feb 07Third quarter 2021 earnings released: EPS JP¥7.55 (vs JP¥41.65 in 3Q 2020)The company reported a poor third quarter result with weaker earnings, revenues and profit margins. Third quarter 2021 results: Revenue: JP¥25.8b (down 9.9% from 3Q 2020). Net income: JP¥365.0m (down 82% from 3Q 2020). Profit margin: 1.4% (down from 7.0% in 3Q 2020). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has increased by 54% per year, which means it is tracking significantly ahead of earnings growth.お知らせ • Jan 22JEOL Ltd. Announces the Release of A New Cold Field Emission Cryo-Electron Microscope, the CRYO ARM™ 300 II (JEM-3300)JEOL Ltd. announced the release of a new cold field emission cryo-electron microscope (cryo-EM), the CRYO ARM™ 300 II (JEM-3300), to be released in January 2021. This new cryo-EM has been developed based on the concept of "Quick and easy to operate and get high-contrast and high-resolution images". Recent dramatic improvement of resolution in single particle analysis (SPA) using cryo-EM has led to SPA as an essential method for structural analysis of proteins. To address this market, JEOL released the CRYO ARM™ 300 in 2017. Equipped with a cold field emission gun (Cold FEG) for enhanced resolution and a cryo-stage for loading multiple samples, the CRYO ARM™ 300 has continued to achieve best-in-class resolution for SPA. However, the previous workflow of SPA using cryo-EM needs multiple electron microscopes because the workflows for sample screening and for image data acquisition are independent of one another. This problem gives rise to large operating costs for cryo-EM users. Since multiple microscopes must be used, it is inconvenient to transfer cryo-samples between the cryo-EMs. Therefore, users have been requesting one cryo-EM enabling the complete workflow from sample screening to image data acquisition. Furthermore, in order for various users to use the cryo-EM, an improvement of usability has been required, allowing anyone from novice users to professional users to smoothly operate the microscope. To meet these requests, JEOL has developed a new cryo-EM, the CRYO ARM™ 300 II. This microscope achieves a great improvement in throughput for high-quality data acquisition with quick and easy operation compared with the previous CRYO ARM™ 300. Main Features: High-speed imaging achieved by optimal electron beam control; Improved hardware stability for high-quality image acquisition; Higher operability through system improvement; Annual unit sales target; 10 units/year.Is New 90 Day High Low • Jan 14New 90-day high: €41.00The company is up 43% from its price of €28.60 on 16 October 2020. The German market is up 10.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Medical Equipment industry, which is up 10.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €36.22 per share.Is New 90 Day High Low • Dec 29New 90-day high: €38.00The company is up 30% from its price of €29.20 on 30 September 2020. The German market is up 9.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Medical Equipment industry, which is up 10.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €36.20 per share.お知らせ • Dec 19JEOL Ltd. to Report Q3, 2021 Results on Feb 05, 2021JEOL Ltd. announced that they will report Q3, 2021 results on Feb 05, 2021Is New 90 Day High Low • Nov 20New 90-day high: €30.80The company is up 25% from its price of €24.60 on 21 August 2020. The German market is up 2.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Medical Equipment industry, which is up 6.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €9.69 per share.Analyst Estimate Surprise Post Earnings • Nov 08Revenue beats expectationsRevenue exceeded analyst estimates by 0.08%. Over the next year, revenue is forecast to grow 4.7%, compared to a 13% growth forecast for the Medical Equipment industry in Germany.Reported Earnings • Nov 08Second quarter 2021 earnings released: EPS JP¥37.61The company reported a poor second quarter result with weaker earnings, revenues and profit margins. Second quarter 2021 results: Revenue: JP¥28.4b (down 12% from 2Q 2020). Net income: JP¥1.82b (down 35% from 2Q 2020). Profit margin: 6.4% (down from 8.7% in 2Q 2020). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 16% per year but the company’s share price has increased by 46% per year, which means it is tracking significantly ahead of earnings growth.お知らせ • Oct 10JEOL Ltd. to Report Q2, 2021 Results on Nov 06, 2020JEOL Ltd. announced that they will report Q2, 2021 results on Nov 06, 2020Is New 90 Day High Low • Oct 08New 90-day high: €30.00The company is up 20% from its price of €25.00 on 10 July 2020. The German market is up 3.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Medical Equipment industry, which is up 2.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €4.70 per share.お知らせ • Sep 24JEOL and ACD/Labs Announces Collaboration to Provide ACD/Labs Software with NMR SpectrometersACD/Labs and JEOL announced that they have entered into a collaborative arrangement that will supply JEOL NMR spectrometer purchasers with ACD/Spectrus Processor software for data processing and analysis. Under the terms of the agreement, JEOL will supply a one-year subscription of ACD/Spectrus Processor at no cost to academics, and for an incremental fee to industry. ACD/Labs' industry-standard software that predicts spectra from structure (ACD/NMR Predictors) and popular advanced processing, interpretation, and databasing application (ACD/NMR Workbook Suite) will also be available to JEOL customers at an incremental cost.Is New 90 Day High Low • Sep 18New 90-day high: €27.80The company is up 10.0% from its price of €25.20 on 19 June 2020. The German market is up 6.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Medical Equipment industry, which is down 4.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €4.65 per share.お知らせ • Jun 17JEOL Ltd. to Report Q1, 2021 Results on Aug 14, 2020JEOL Ltd. announced that they will report Q1, 2021 results on Aug 14, 2020業績と収益の成長予測DB:JEL - アナリストの将来予測と過去の財務データ ( )JPY Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数3/31/2028191,54625,521N/AN/A43/31/2027181,05922,700N/AN/A63/31/2026182,99019,873N/AN/A612/31/2025190,14716,243N/AN/AN/A9/30/2025191,52017,6227,09914,896N/A6/30/2025200,48619,461N/AN/AN/A3/31/2025196,69518,68818,84123,104N/A12/31/2024203,81131,494N/AN/AN/A9/30/2024192,85225,10427,60331,145N/A6/30/2024182,01923,876N/AN/AN/A3/31/2024174,33621,70411,82615,301N/A12/31/2023161,87114,710N/AN/AN/A9/30/2023166,66418,117-4432,625N/A6/30/2023162,50416,339N/AN/AN/A3/31/2023162,68917,830-3,0383,351N/A12/31/2022155,28618,213N/AN/AN/A9/30/2022149,78315,84213,59719,297N/A6/30/2022143,47014,730N/AN/AN/A3/31/2022138,40812,27821,08822,603N/A12/31/2021126,0278,779N/AN/AN/A9/30/2021114,4195,4785,7928,130N/A6/30/2021113,2854,393N/AN/AN/A3/31/2021110,4393,745-3,6713,358N/A12/31/2020112,6914,415N/AN/AN/A9/30/2020115,5196,062-5,6991,441N/A6/30/2020119,4497,052N/AN/AN/A3/31/2020117,2435,3598363,742N/A12/31/2019117,7846,492N/AN/AN/A9/30/2019115,6795,788N/A4,491N/A6/30/2019110,0735,094N/AN/AN/A3/31/2019111,2895,940N/A4,757N/A12/31/2018110,0396,323N/AN/AN/A9/30/2018110,5936,644N/A8,384N/A6/30/2018108,7275,925N/AN/AN/A3/31/2018104,5704,532N/A6,524N/A12/31/2017101,8173,710N/AN/AN/A9/30/201795,9612,431N/A3,077N/A6/30/201796,426695N/AN/AN/A3/31/201799,698595N/A-573N/A12/31/2016101,484-306N/AN/AN/A9/30/2016105,289223N/A-330N/A6/30/2016108,2591,977N/AN/AN/A3/31/2016107,3734,089N/A8,137N/A12/31/2015107,5405,844N/AN/AN/A9/30/2015103,2015,536N/A7,271N/A6/30/201597,5974,568N/AN/AN/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: JELの予測収益成長率 (年間17.7% ) は 貯蓄率 ( 1.9% ) を上回っています。収益対市場: JELの収益 ( 17.7% ) はGerman市場 ( 16.7% ) よりも速いペースで成長すると予測されています。高成長収益: JELの収益は増加すると予測されていますが、大幅には増加しません。収益対市場: JELの収益 ( 0.3% ) German市場 ( 6.4% ) よりも低い成長が予測されています。高い収益成長: JELの収益 ( 0.3% ) 20%よりも低い成長が予測されています。一株当たり利益成長率予想将来の株主資本利益率将来のROE: JELの 自己資本利益率 は、3年後には低くなると予測されています ( 14.7 %)。成長企業の発掘7D1Y7D1Y7D1YTech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/06 09:21終値2026/05/06 00:00収益2025/12/31年間収益2025/03/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋JEOL Ltd. 6 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。11 アナリスト機関Masahiro NakanomyoBarclaysMayako OuchiBofA Global ResearchShuhei NakamuraGoldman Sachs8 その他のアナリストを表示
お知らせ • Feb 02JEOL Ltd. (TSE:6951) announces an Equity Buyback for 2,500,000 shares, representing 4.88% for ¥12,870 million.JEOL Ltd. (TSE:6951) announces a share repurchase program. Under the program, the company will repurchase up to 2,500,000 shares, representing 4.88% of its issued share capital, for ¥12,870 million. Shares will be repurchased at a price of ¥5,148 per share. Under the offer the company will repurchase 2,300,000 shares from Nikon Corporation. The purpose of the program is returning profits to shareholders and to enable the agile implementation of capital policies in response to changes in the business environment. If the number of tendered shares exceed the number of shares to be purchased then the actual number of shares purchased may exceed the number of shares to be purchased as a result of unit adjustment on a pro rata basis. The offer is valid till March 4, 2026. As of September 30, 2025, the company had 51,181,974 shares (excluding treasury shares) and 350,826 shares in treasury.
お知らせ • Dec 06JEOL Ltd. to Report Q3, 2026 Results on Feb 13, 2026JEOL Ltd. announced that they will report Q3, 2026 results on Feb 13, 2026
お知らせ • Sep 26JEOL Ltd. to Report Q2, 2026 Results on Nov 14, 2025JEOL Ltd. announced that they will report Q2, 2026 results on Nov 14, 2025
お知らせ • Jun 27JEOL Ltd. to Report Q1, 2026 Results on Aug 13, 2025JEOL Ltd. announced that they will report Q1, 2026 results on Aug 13, 2025
お知らせ • May 15JEOL Ltd., Annual General Meeting, Jun 26, 2025JEOL Ltd., Annual General Meeting, Jun 26, 2025.
お知らせ • Mar 15JEOL Ltd. to Report Fiscal Year 2025 Results on May 15, 2025JEOL Ltd. announced that they will report fiscal year 2025 results on May 15, 2025
お知らせ • Dec 04JEOL Ltd. to Report Q3, 2025 Results on Feb 12, 2025JEOL Ltd. announced that they will report Q3, 2025 results on Feb 12, 2025
お知らせ • Nov 26JEOL Ltd. (TSE:6951) agreed to acquire an additional majority stake in Japan Superconductor Technology, Inc. from Kobe Steel, Ltd. (TSE:5406).JEOL Ltd. (TSE:6951) agreed to acquire an additional majority stake in Japan Superconductor Technology, Inc. from Kobe Steel, Ltd. (TSE:5406) on November 22, 2024. Post the closing of the transaction, Kobe Steel will not hold any stake in Japan Superconductor Technology. For the period ending March 31, 2024, Japan Superconductor Technology, Inc. reported total revenue of ¥4.14 billion. The expected completion of the transaction is January 6, 2025.
Reported Earnings • Nov 10Second quarter 2025 earnings released: EPS: JP¥137 (vs JP¥113 in 2Q 2024)Second quarter 2025 results: EPS: JP¥137 (up from JP¥113 in 2Q 2024). Revenue: JP¥50.9b (up 27% from 2Q 2024). Net income: JP¥7.02b (up 21% from 2Q 2024). Profit margin: 14% (in line with 2Q 2024). Revenue is forecast to grow 4.0% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Electronic industry in Germany. Over the last 3 years on average, earnings per share has increased by 30% per year but the company’s share price has fallen by 20% per year, which means it is significantly lagging earnings.
Buy Or Sell Opportunity • Nov 09Now 21% overvalued after recent price riseOver the last 90 days, the stock has risen 11% to €36.40. The fair value is estimated to be €30.06, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 15% over the last 3 years. Earnings per share has grown by 35%. Revenue is forecast to grow by 13% in 2 years. Earnings are forecast to grow by 24% in the next 2 years.
Buy Or Sell Opportunity • Oct 15Now 20% overvaluedOver the last 90 days, the stock has fallen 9.4% to €36.80. The fair value is estimated to be €30.65, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 15% over the last 3 years. Earnings per share has grown by 35%. Revenue is forecast to grow by 13% in 2 years. Earnings are forecast to grow by 24% in the next 2 years.
お知らせ • Sep 27JEOL Ltd. to Report Q2, 2025 Results on Nov 08, 2024JEOL Ltd. announced that they will report Q2, 2025 results on Nov 08, 2024
Upcoming Dividend • Sep 20Upcoming dividend of JP¥44.00 per shareEligible shareholders must have bought the stock before 27 September 2024. Payment date: 11 December 2024. Payout ratio is a comfortable 18% and this is well supported by cash flows. Trailing yield: 1.7%. Lower than top quartile of German dividend payers (4.8%). In line with average of industry peers (1.8%).
お知らせ • Sep 04JEOL Ltd. Announces the Release of the New CROSS SECTION POLISHER IB-19540CP / COOLING CROSS SECTION POLISHER IB-19550CCP for Electron MicroscopesJEOL Ltd. announced the release of the New CROSS SECTION POLISHER IB-19540CP /COOLING CROSS SECTION POLISHER IB-19550CCP for Electron Microscopes on September 4, 2024. CROSS SECTION POLISHER™(CP)is widely utilized in the fields of electronic parts, ceramics, life science, metal, battery, and polymer. The mechanical high-quality uniform cross section can be easily prepared for complex materials and fragile specimens. With a sales record of over 2,000 units since its launch in 2003, the CP has been an essential tool for pre-treatment. The IB-19540CP /IB-19550CCP have been advanced with enhanced user-friendliness. Incorporation of the new GUI and IoT (Internet of Things) further improves ease of use and enables remote control and milling process monitoring by PC. High throughput ion source and high throughput cooling system enable preparation of a smooth cross section rapidly with less damages. Main features: New GUI and Internet of Things (IoT) - Incorporation of a new GUI makes the operation steps easy to understand. Easy setup is possible by following the flowchart on the control panel. Preset functions are available for saving and recalling process conditions tailored to specific applications or specimen types. Connecting to LAN provides remote access and control through a web browser to the CP. Monitoring and adjusting the milling process over multiple CPs is possible. High throughput ion source: High throughput ion source is equipped as a standard. The ion current density has been improved by optimizing the ion-source electrode and increasing the accelerating voltage. The standard cross section milling rate is now 1,200 µm/h and it will help reduce the time required for processing. Milling of 1 h, Si equivalent, Edge distance: 100 µm. High throughput cooling system: The high throughput cooling system and the new GUI enable automatic operation from cooling to return to room temperature. Thus, the waiting time has been reduced and it helps shorten the time required for work. It is possible to vacuum around the liquid nitrogen tank from the CP side to maintain cooling retention time and specimen cooling temperature. Annual Unit Sales Target - 180 units/year.
Valuation Update With 7 Day Price Move • Aug 22Investor sentiment improves as stock rises 15%After last week's 15% share price gain to €39.20, the stock trades at a forward P/E ratio of 13x. Average forward P/E is 15x in the Electronic industry in Germany. Total loss to shareholders of 31% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €30.89 per share.
Reported Earnings • Aug 18First quarter 2025 earnings released: EPS: JP¥76.26 (vs JP¥33.76 in 1Q 2024)First quarter 2025 results: EPS: JP¥76.26 (up from JP¥33.76 in 1Q 2024). Revenue: JP¥36.4b (up 27% from 1Q 2024). Net income: JP¥3.90b (up 126% from 1Q 2024). Profit margin: 11% (up from 6.0% in 1Q 2024). The increase in margin was driven by higher revenue. Revenue is forecast to grow 5.9% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Electronic industry in Germany. Over the last 3 years on average, earnings per share has increased by 35% per year but the company’s share price has fallen by 11% per year, which means it is significantly lagging earnings.
Buy Or Sell Opportunity • Aug 18Now 24% overvaluedOver the last 90 days, the stock has fallen 2.1% to €37.80. The fair value is estimated to be €30.58, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 15% over the last 3 years. Earnings per share has grown by 35%. Revenue is forecast to grow by 12% in 2 years. Earnings are forecast to grow by 23% in the next 2 years.
New Risk • Aug 05New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 7.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company.
Valuation Update With 7 Day Price Move • Aug 05Investor sentiment deteriorates as stock falls 18%After last week's 18% share price decline to €28.80, the stock trades at a forward P/E ratio of 9x. Average forward P/E is 15x in the Electronic industry in Germany. Total loss to shareholders of 50% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €11.70 per share.
お知らせ • Jul 31JEOL Ltd. Announces New Schottky Field Emission Scanning Electron Microscope JSM-IT810 ReleasedJEOL Ltd. announced the release of the new Schottky Field Emission Scanning Electron Microscope JSM-IT810 on July 28, 2024. Field Emission Scanning Electron Microscopes (FESEM) are widely used in science and technology fields such as research institutes, universities, and industry. There is a growing demand for an instrument that can be used easily, accurately, quickly, and efficiently from observation to analysis. The JSM-IT810 adds the "Neo Action" automatic observation and analysis function and automatic calibration function to the JSM-IT800, which is equipped with the next-generation electron optical control system “Neo Engine” and the “SEM Center” for high operability such as Zeromag and EDS integration, to not only improve efficiency and productivity but also help solve labor shortages. Main Features: 1. Automatic Observation and Analysis Function “Neo Action”: All you need to do is select the SEM image acquisition conditions and field of view, and the function automatically performs SEM observation and EDS (energy dispersive X-ray spectroscopy) analysis. This function contributes to improving the efficiency of routine work including analysis work. 2. Automatic Calibration Function “SEM Automatic Adjustment Package”: This function enables automatic execution of the selected items in alignment adjustment, magnification adjustment, and EDS energy calibration. 3. “Live Function”: This function is capable of Live 3D, Live Analysis, and Live Map functions. 3D images can be constructed on the spot while an SEM observation is being performed to obtain unevenness and depth information. In addition, it helps always display characteristic X-ray spectrum and elemental mapping. 4. EDS Integration: Observation by an SEM and analysis by an EDS are integrated. Analysis of point, area, and MAP can be performed from the observation screen. Incorporation of the Windowless EDS-Gather-X enables detection from Li and analysis at a high sensitivity and high spatial resolution.
お知らせ • May 30JEOL Ltd. Announces the Release of the New Electron Microscope JEM-120iJEOL Ltd. announced the release of the new electron microscope JEM-120i developed with the concepts of “Compact”, “Easy To Use”, and “Expandable” on May 30, 2024. Electron microscopes are utilized in a wide range of fields from biotechnology to nano technology, polymers, and advanced materials. With the expansion of application, usages are also expanding, which requires a tool that is easy-to-use for research and testing purposes. To satisfy such needs, the JEM-120i has evolved into a next-generation microscope that is easy to use, from operation to maintenance, for both beginner and experienced users. Compact: The JEM-120i adopts a totally new appearance and compact design that fits any installation location. The footprint has been reduced by more than 50%, and the volume occupied by the instrument is less than one-third of that of conventional models, enabling effective use of space. The instrument height is lower than 1,800mm, which fits just about any installation room. Easy to Use: The enhanced TEM control system and fully automated apertures eliminated the need for switching the magnification mode and selecting an aperture. The JEM-120i provides seamless observations from low to high magnification. It takes only 4 steps from loading a specimen to completing an observation. After inserting the specimen holder, clicking the Start Button automatically performs observation preparation operations such as voltage increase and emission start. A wide area image is captured at the same time, and clicking the target field of view will complete the stage movement. Standard “Butler mode” assists data acquisition. Even a beginner can capture data easily. Expandable: In addition to the standard multi-function camera, a bottom-mount camera of higher pixel count can be selected as an option. Attachments such as the scanning image observation function (STEM), elemental analysis function (EDS), and cryo observation function can be applied, regardless of instrument configuration. The instrument can be expanded at any time to meet the changing needs of microscopy over time. The proven scripting function (PyJEM) with the high-end models, can create an algorithm for automation. The automation can increase the utilization rate of the instrument and improve data output efficiency. Main Specifications: Resolution- 0.2 nm (HC), 0.14 nm (HR). Accelerating voltage- 20-120kV. Magnification- 50-1,200,000 (HC), 50-1,500,000 (HR). Standard camera- JEOL CMOS camera (NeoView) 4M pixel, 30fps. Field of view search/adjustment/recording. Optional camera- JEOL CMOS camera (SightSKY) 19M pixel, 58fps. Cameras made by other companies can also be mounted. Main unit dimensions: W 840mm/D 1,734mm/H 1,782mm.
Reported Earnings • May 19Full year 2024 earnings released: EPS: JP¥425 (vs JP¥349 in FY 2023)Full year 2024 results: EPS: JP¥425 (up from JP¥349 in FY 2023). Revenue: JP¥174.3b (up 7.2% from FY 2023). Net income: JP¥21.7b (up 22% from FY 2023). Profit margin: 12% (up from 11% in FY 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 7.6% p.a. on average during the next 3 years, compared to a 6.9% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 40% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings.
お知らせ • May 16JEOL Ltd., Annual General Meeting, Jun 26, 2024JEOL Ltd., Annual General Meeting, Jun 26, 2024.
お知らせ • May 15JEOL Ltd. Announces Resignation of Gon-Emon Kurihara as ChairmanJEOL Ltd. announced the resignation of Gon-emon Kurihara as chairman of the company due to expiration of term.
Upcoming Dividend • Mar 21Upcoming dividend of JP¥41.00 per shareEligible shareholders must have bought the stock before 28 March 2024. Payment date: 01 July 2024. Payout ratio is a comfortable 24% but the company is not cash flow positive. Trailing yield: 1.2%. Lower than top quartile of German dividend payers (5.0%). Lower than average of industry peers (1.6%).
お知らせ • Mar 02JEOL Ltd. to Report Fiscal Year 2024 Results on May 14, 2024JEOL Ltd. announced that they will report fiscal year 2024 results on May 14, 2024
Reported Earnings • Feb 11Third quarter 2024 earnings released: EPS: JP¥51.48 (vs JP¥118 in 3Q 2023)Third quarter 2024 results: EPS: JP¥51.48 (down from JP¥118 in 3Q 2023). Revenue: JP¥38.2b (down 11% from 3Q 2023). Net income: JP¥2.63b (down 56% from 3Q 2023). Profit margin: 6.9% (down from 14% in 3Q 2023). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 7.2% p.a. on average during the next 3 years, compared to a 6.5% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 43% per year but the company’s share price has only increased by 4% per year, which means it is significantly lagging earnings growth.
Buy Or Sell Opportunity • Jan 31Now 20% undervaluedOver the last 90 days, the stock has risen 43% to €42.80. The fair value is estimated to be €53.72, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 16% over the last 3 years. Earnings per share has grown by 48%. Revenue is forecast to grow by 12% in 2 years. Earnings are forecast to grow by 23% in the next 2 years.
Valuation Update With 7 Day Price Move • Jan 26Investor sentiment improves as stock rises 21%After last week's 21% share price gain to €45.40, the stock trades at a forward P/E ratio of 19x. Average forward P/E is 25x in the Medical Equipment industry in Germany. Total returns to shareholders of 35% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €53.32 per share.
お知らせ • Nov 27JEOL Ltd. to Report Q3, 2024 Results on Feb 09, 2024JEOL Ltd. announced that they will report Q3, 2024 results on Feb 09, 2024
New Risk • Nov 14New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 6.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company.
Reported Earnings • Nov 12Second quarter 2024 earnings released: EPS: JP¥113 (vs JP¥78.63 in 2Q 2023)Second quarter 2024 results: EPS: JP¥113 (up from JP¥78.63 in 2Q 2023). Revenue: JP¥40.0b (up 12% from 2Q 2023). Net income: JP¥5.79b (up 44% from 2Q 2023). Profit margin: 14% (up from 11% in 2Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 5.0% p.a. on average during the next 3 years, compared to a 6.1% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 48% per year but the company’s share price has only increased by 2% per year, which means it is significantly lagging earnings growth.
Valuation Update With 7 Day Price Move • Nov 07Investor sentiment improves as stock rises 17%After last week's 17% share price gain to €31.00, the stock trades at a forward P/E ratio of 15x. Average forward P/E is 24x in the Medical Equipment industry in Germany. Total returns to shareholders of 10% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €48.84 per share.
Upcoming Dividend • Sep 21Upcoming dividend of JP¥33.00 per share at 1.4% yieldEligible shareholders must have bought the stock before 28 September 2023. Payment date: 12 December 2023. Payout ratio is a comfortable 21% but the company is not cash flow positive. Trailing yield: 1.4%. Lower than top quartile of German dividend payers (4.8%). Lower than average of industry peers (2.0%).
お知らせ • Aug 31JEOL Ltd. to Report Q2, 2024 Results on Nov 10, 2023JEOL Ltd. announced that they will report Q2, 2024 results on Nov 10, 2023
Reported Earnings • Aug 13First quarter 2024 earnings released: EPS: JP¥33.76 (vs JP¥63.03 in 1Q 2023)First quarter 2024 results: EPS: JP¥33.76 (down from JP¥63.03 in 1Q 2023). Revenue: JP¥28.7b (flat on 1Q 2023). Net income: JP¥1.72b (down 46% from 1Q 2023). Profit margin: 6.0% (down from 11% in 1Q 2023). Revenue is forecast to grow 3.7% p.a. on average during the next 3 years, compared to a 6.3% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 47% per year but the company’s share price has only increased by 3% per year, which means it is significantly lagging earnings growth.
お知らせ • Jun 03JEOL Ltd. to Report Q1, 2024 Results on Aug 10, 2023JEOL Ltd. announced that they will report Q1, 2024 results on Aug 10, 2023
Reported Earnings • May 16Full year 2023 earnings released: EPS: JP¥349 (vs JP¥247 in FY 2022)Full year 2023 results: EPS: JP¥349 (up from JP¥247 in FY 2022). Revenue: JP¥162.7b (up 18% from FY 2022). Net income: JP¥17.8b (up 45% from FY 2022). Profit margin: 11% (up from 8.9% in FY 2022). The increase in margin was driven by higher revenue. Revenue is forecast to grow 3.3% p.a. on average during the next 3 years, compared to a 6.4% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 49% per year but the company’s share price has remained flat, which means it is significantly lagging earnings.
お知らせ • May 14JEOL Ltd., Annual General Meeting, Jun 28, 2023JEOL Ltd., Annual General Meeting, Jun 28, 2023.
Upcoming Dividend • Mar 23Upcoming dividend of JP¥30.00 per share at 1.6% yieldEligible shareholders must have bought the stock before 30 March 2023. Payment date: 29 June 2023. Payout ratio is a comfortable 18% and this is well supported by cash flows. Trailing yield: 1.6%. Lower than top quartile of German dividend payers (4.7%). In line with average of industry peers (1.7%).
Reported Earnings • Feb 13Third quarter 2023 earnings released: EPS: JP¥118 (vs JP¥71.86 in 3Q 2022)Third quarter 2023 results: EPS: JP¥118 (up from JP¥71.86 in 3Q 2022). Revenue: JP¥43.0b (up 15% from 3Q 2022). Net income: JP¥6.04b (up 65% from 3Q 2022). Profit margin: 14% (up from 9.8% in 3Q 2022). The increase in margin was driven by higher revenue. Revenue is forecast to grow 4.3% p.a. on average during the next 3 years, compared to a 6.3% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 44% per year but the company’s share price has fallen by 2% per year, which means it is significantly lagging earnings.
お知らせ • Feb 01JEOL Ltd. Announces its Launch of the FIB-SEM system “JIB-PS500i”JEOL Ltd. announced its launch of the FIB-SEM system “JIB-PS500i” on February 1, 2023. With the finer structure of advanced materials and advancing complexity of processes, evaluation techniques such as morphological observation and elemental analysis require higher resolution and precision. In the preparation of samples for transmission electron microscopes (TEM) in the semiconductor industry as well as in the battery and materials fields, "higher precision" and "thinner sample" are required. This product is a combined system of the FIB (Focused Ion Beam) system that can process with high accuracy and the SEM (scanning electron microscope) of high resolution to satisfy these needs. Main Features: The FIB column enables processing with a large-current Ga ion beam up to 100nA. The high-current processing is particularly effective in preparing cross section samples for large-area imaging and analysis. In addition, the FIB column is set to a shorter working distance. Along with a newly-developed power supply, it has led to greatly improved processing performance at a low accelerating voltage. A newly-developed super conical lens system is built into the SEM column, greatly improving the image resolution at a low accelerating voltage. This superb imaging is very useful to check the end-point milling status of lamella specimen using the SEM. The JIB-PS500i adopts a large specimen chamber and a newly-developed specimen stage, increasing the stage movement range, and thus accommodating a large specimen. In addition, a newly-developed STEM detector that can be used with the stage tilt at 90 degrees, allows for a seamless transition from the TEM specimen preparation to STEM observation. For the operating GUI, the “SEM center”, which has been well received in the JSM-IT800 series of high-resolution scanning electron microscopes is employed, enabling full integration of EDS analysis. A double tilt cartridge and a dedicated TEM holder allows for more precise alignment while making specimen transfer between TEM and FIB easier.
Reported Earnings • Nov 16Second quarter 2023 earnings released: EPS: JP¥78.63 (vs JP¥59.59 in 2Q 2022)Second quarter 2023 results: EPS: JP¥78.63 (up from JP¥59.59 in 2Q 2022). Revenue: JP¥35.9b (up 21% from 2Q 2022). Net income: JP¥4.01b (up 38% from 2Q 2022). Profit margin: 11% (up from 9.8% in 2Q 2022). The increase in margin was driven by higher revenue. Revenue is forecast to grow 5.2% p.a. on average during the next 3 years, compared to a 6.2% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 36% per year but the company’s share price has only increased by 14% per year, which means it is significantly lagging earnings growth.
Board Change • Nov 16Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, 1 was an independent director. The company's board is composed of: 2 independent directors. 6 non-independent directors. Independent Outside Director Ryuji Kanno was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity.
Reported Earnings • Nov 13Second quarter 2023 earnings released: EPS: JP¥78.63 (vs JP¥59.59 in 2Q 2022)Second quarter 2023 results: EPS: JP¥78.63 (up from JP¥59.59 in 2Q 2022). Revenue: JP¥35.9b (up 21% from 2Q 2022). Net income: JP¥4.01b (up 38% from 2Q 2022). Profit margin: 11% (up from 9.8% in 2Q 2022). The increase in margin was driven by higher revenue. Revenue is forecast to grow 6.0% p.a. on average during the next 3 years, compared to a 6.3% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 36% per year but the company’s share price has only increased by 18% per year, which means it is significantly lagging earnings growth.
Upcoming Dividend • Sep 22Upcoming dividend of JP¥30.00 per shareEligible shareholders must have bought the stock before 29 September 2022. Payment date: 06 December 2022. Payout ratio is a comfortable 17% and this is well supported by cash flows. Trailing yield: 1.1%. Lower than top quartile of German dividend payers (5.1%). Lower than average of industry peers (1.8%).
お知らせ • Sep 14+ 1 more updateJEOL Ltd. to Report Q2, 2023 Results on Nov 11, 2022JEOL Ltd. announced that they will report Q2, 2023 results on Nov 11, 2022
Reported Earnings • Aug 14First quarter 2023 earnings released: EPS: JP¥63.02 (vs JP¥15.79 in 1Q 2022)First quarter 2023 results: EPS: JP¥63.02 (up from JP¥15.79 in 1Q 2022). Revenue: JP¥28.9b (up 21% from 1Q 2022). Net income: JP¥3.22b (up 321% from 1Q 2022). Profit margin: 11% (up from 3.2% in 1Q 2022). The increase in margin was driven by higher revenue. Over the next year, revenue is forecast to grow 14%, compared to a 7.5% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 28% per year whereas the company’s share price has increased by 32% per year.
お知らせ • Jun 23JEOL Ltd. to Report Q1, 2023 Results on Aug 12, 2022JEOL Ltd. announced that they will report Q1, 2023 results on Aug 12, 2022
Reported Earnings • May 17Full year 2022 earnings released: EPS: JP¥247 (vs JP¥77.51 in FY 2021)Full year 2022 results: EPS: JP¥247 (up from JP¥77.51 in FY 2021). Revenue: JP¥138.4b (up 25% from FY 2021). Net income: JP¥12.3b (up 228% from FY 2021). Profit margin: 8.9% (up from 3.4% in FY 2021). The increase in margin was driven by higher revenue. Over the next year, revenue is forecast to grow 11%, compared to a 7.1% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has increased by 36% per year, which means it is tracking significantly ahead of earnings growth.
お知らせ • May 15JEOL Ltd., Annual General Meeting, Jun 28, 2022JEOL Ltd., Annual General Meeting, Jun 28, 2022.
Board Change • Apr 27Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 7 non-independent directors. Independent Outside Director Ryuji Kanno was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Apr 08JEOL Ltd. to Report Fiscal Year 2022 Results on May 13, 2022JEOL Ltd. announced that they will report fiscal year 2022 results on May 13, 2022
Buying Opportunity • Mar 29Now 22% undervalued after recent price dropOver the last 90 days, the stock is down 32%. The fair value is estimated to be JP¥61.26, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Earnings per share has been flat over the last 3 years.
Upcoming Dividend • Mar 23Upcoming dividend of JP¥14.00 per shareEligible shareholders must have bought the stock before 30 March 2022. Payment date: 28 June 2022. Payout ratio is a comfortable 21% and this is well supported by cash flows. Trailing yield: 0.4%. Lower than top quartile of German dividend payers (3.6%). Lower than average of industry peers (1.1%).
Valuation Update With 7 Day Price Move • Mar 22Investor sentiment improved over the past weekAfter last week's 17% share price gain to €49.00, the stock trades at a forward P/E ratio of 24x. Average forward P/E is 34x in the Medical Equipment industry in Germany. Total returns to shareholders of 222% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €65.72 per share.
Reported Earnings • Feb 06Third quarter 2022 earnings: EPS in line with analyst expectations despite revenue beatThird quarter 2022 results: EPS: JP¥71.85 (up from JP¥7.55 in 3Q 2021). Revenue: JP¥37.4b (up 45% from 3Q 2021). Net income: JP¥3.67b (up JP¥3.30b from 3Q 2021). Profit margin: 9.8% (up from 1.4% in 3Q 2021). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 8.0%. Over the next year, revenue is forecast to grow 15%, compared to a 12% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has remained flat but the company’s share price has increased by 47% per year, which means it is well ahead of earnings.
Buying Opportunity • Jan 22Now 22% undervalued after recent price dropOver the last 90 days, the stock is down 23%. The fair value is estimated to be JP¥62.70, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Earnings per share has declined by 10% per annum over the last 3 years.
Valuation Update With 7 Day Price Move • Jan 10Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to €59.50, the stock trades at a forward P/E ratio of 37x. Average forward P/E is 36x in the Medical Equipment industry in Germany. Total returns to shareholders of 344% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €61.71 per share.
Reported Earnings • Nov 06Second quarter 2022 earnings released: EPS JP¥59.58 (vs JP¥37.61 in 2Q 2021)The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2022 results: Revenue: JP¥29.6b (up 4.0% from 2Q 2021). Net income: JP¥2.90b (up 60% from 2Q 2021). Profit margin: 9.8% (up from 6.4% in 2Q 2021). Over the last 3 years on average, earnings per share has fallen by 10% per year but the company’s share price has increased by 66% per year, which means it is well ahead of earnings.
Upcoming Dividend • Sep 22Upcoming dividend of JP¥14.00 per shareEligible shareholders must have bought the stock before 29 September 2021. Payment date: 04 December 2021. Trailing yield: 0.3%. Lower than top quartile of German dividend payers (3.2%). Lower than average of industry peers (0.8%).
Valuation Update With 7 Day Price Move • Jun 04Investor sentiment improved over the past weekAfter last week's 16% share price gain to JP¥45.80, the stock trades at a forward P/E ratio of 41x. Average forward P/E is 47x in the Medical Equipment industry in Germany. Total returns to shareholders of 162% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €38.38 per share.
Reported Earnings • May 17Full year 2021 earnings released: EPS JP¥77.51 (vs JP¥111 in FY 2020)The company reported a poor full year result with weaker earnings, revenues and profit margins. Full year 2021 results: Revenue: JP¥110.4b (down 5.8% from FY 2020). Net income: JP¥3.75b (down 30% from FY 2020). Profit margin: 3.4% (down from 4.6% in FY 2020). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has fallen by 5% per year but the company’s share price has increased by 29% per year, which means it is well ahead of earnings.
Valuation Update With 7 Day Price Move • Apr 17Investor sentiment improved over the past weekAfter last week's 31% share price gain to JP¥45.20, the stock trades at a forward P/E ratio of 43x. Average forward P/E is 50x in the Medical Equipment industry in Germany. Total returns to shareholders of 238% over the past three years.
Upcoming Dividend • Mar 24Upcoming dividend of JP¥12.00 per shareEligible shareholders must have bought the stock before 30 March 2021. Payment date: 26 June 2021. Trailing yield: 0.6%. Lower than top quartile of German dividend payers (3.3%). Lower than average of industry peers (1.0%).
Is New 90 Day High Low • Feb 25New 90-day low: €31.00The company is down 9.0% from its price of €34.20 on 26 November 2020. The German market is up 7.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is up 21% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €36.38 per share.
お知らせ • Feb 18JEOL Ltd. Releases JMS-T2000GC AccuTOF(TM) GC-AlphaJEOL Ltd. announced the release of JMS-T2000GC AccuTOF(TM) GC-Alpha, the latest model of the successful AccuTOF(TM) GC series gas chromatograph – time-of-flight mass spectrometers, to be released in February 2021. This product is a GC-MS that represents a significant improvement in performance and functionality using two newly developed Key Technologies. The basic hardware performance has been greatly improved and a new generation of automated data analysis software is included in the standard configuration. The JMS-T2000GC AccuTOF(TM) GC-Alpha, the 6th generation of the successful AccuTOF(TM) GC series, achieves three times the mass resolving power and mass measurement accuracy of the previous AccuTOF(TM) GCx-plus by using a whole new ion optics design that achieves excellent sensitivity and high data acquisition speed, the long-time hallmarks for the AccuTOF(TM) GC series. Additionally, the system has a wide dynamic range that is beneficial not only for quantitative analysis but also for qualitative analysis of complex mixtures. A wide variety of ionization techniques – field ionization (FI), field desorption (FD), photoionization (PI), and chemical ionization (CI) – are optionally available, in addition to the standard electron ionization (EI). Two combination ion sources are also available as options – the EI/FI/FD combination ion source and the EI/PI combination ion source which allow easy switching between ionization techniques without breaking vacuum or replacing the ion sources.
Analyst Estimate Surprise Post Earnings • Feb 07Revenue misses expectationsRevenue missed analyst estimates by 7.7%. Over the next year, revenue is forecast to grow 8.0%, compared to a 14% growth forecast for the Medical Equipment industry in Germany.
Reported Earnings • Feb 07Third quarter 2021 earnings released: EPS JP¥7.55 (vs JP¥41.65 in 3Q 2020)The company reported a poor third quarter result with weaker earnings, revenues and profit margins. Third quarter 2021 results: Revenue: JP¥25.8b (down 9.9% from 3Q 2020). Net income: JP¥365.0m (down 82% from 3Q 2020). Profit margin: 1.4% (down from 7.0% in 3Q 2020). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has increased by 54% per year, which means it is tracking significantly ahead of earnings growth.
お知らせ • Jan 22JEOL Ltd. Announces the Release of A New Cold Field Emission Cryo-Electron Microscope, the CRYO ARM™ 300 II (JEM-3300)JEOL Ltd. announced the release of a new cold field emission cryo-electron microscope (cryo-EM), the CRYO ARM™ 300 II (JEM-3300), to be released in January 2021. This new cryo-EM has been developed based on the concept of "Quick and easy to operate and get high-contrast and high-resolution images". Recent dramatic improvement of resolution in single particle analysis (SPA) using cryo-EM has led to SPA as an essential method for structural analysis of proteins. To address this market, JEOL released the CRYO ARM™ 300 in 2017. Equipped with a cold field emission gun (Cold FEG) for enhanced resolution and a cryo-stage for loading multiple samples, the CRYO ARM™ 300 has continued to achieve best-in-class resolution for SPA. However, the previous workflow of SPA using cryo-EM needs multiple electron microscopes because the workflows for sample screening and for image data acquisition are independent of one another. This problem gives rise to large operating costs for cryo-EM users. Since multiple microscopes must be used, it is inconvenient to transfer cryo-samples between the cryo-EMs. Therefore, users have been requesting one cryo-EM enabling the complete workflow from sample screening to image data acquisition. Furthermore, in order for various users to use the cryo-EM, an improvement of usability has been required, allowing anyone from novice users to professional users to smoothly operate the microscope. To meet these requests, JEOL has developed a new cryo-EM, the CRYO ARM™ 300 II. This microscope achieves a great improvement in throughput for high-quality data acquisition with quick and easy operation compared with the previous CRYO ARM™ 300. Main Features: High-speed imaging achieved by optimal electron beam control; Improved hardware stability for high-quality image acquisition; Higher operability through system improvement; Annual unit sales target; 10 units/year.
Is New 90 Day High Low • Jan 14New 90-day high: €41.00The company is up 43% from its price of €28.60 on 16 October 2020. The German market is up 10.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Medical Equipment industry, which is up 10.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €36.22 per share.
Is New 90 Day High Low • Dec 29New 90-day high: €38.00The company is up 30% from its price of €29.20 on 30 September 2020. The German market is up 9.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Medical Equipment industry, which is up 10.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €36.20 per share.
お知らせ • Dec 19JEOL Ltd. to Report Q3, 2021 Results on Feb 05, 2021JEOL Ltd. announced that they will report Q3, 2021 results on Feb 05, 2021
Is New 90 Day High Low • Nov 20New 90-day high: €30.80The company is up 25% from its price of €24.60 on 21 August 2020. The German market is up 2.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Medical Equipment industry, which is up 6.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €9.69 per share.
Analyst Estimate Surprise Post Earnings • Nov 08Revenue beats expectationsRevenue exceeded analyst estimates by 0.08%. Over the next year, revenue is forecast to grow 4.7%, compared to a 13% growth forecast for the Medical Equipment industry in Germany.
Reported Earnings • Nov 08Second quarter 2021 earnings released: EPS JP¥37.61The company reported a poor second quarter result with weaker earnings, revenues and profit margins. Second quarter 2021 results: Revenue: JP¥28.4b (down 12% from 2Q 2020). Net income: JP¥1.82b (down 35% from 2Q 2020). Profit margin: 6.4% (down from 8.7% in 2Q 2020). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 16% per year but the company’s share price has increased by 46% per year, which means it is tracking significantly ahead of earnings growth.
お知らせ • Oct 10JEOL Ltd. to Report Q2, 2021 Results on Nov 06, 2020JEOL Ltd. announced that they will report Q2, 2021 results on Nov 06, 2020
Is New 90 Day High Low • Oct 08New 90-day high: €30.00The company is up 20% from its price of €25.00 on 10 July 2020. The German market is up 3.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Medical Equipment industry, which is up 2.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €4.70 per share.
お知らせ • Sep 24JEOL and ACD/Labs Announces Collaboration to Provide ACD/Labs Software with NMR SpectrometersACD/Labs and JEOL announced that they have entered into a collaborative arrangement that will supply JEOL NMR spectrometer purchasers with ACD/Spectrus Processor software for data processing and analysis. Under the terms of the agreement, JEOL will supply a one-year subscription of ACD/Spectrus Processor at no cost to academics, and for an incremental fee to industry. ACD/Labs' industry-standard software that predicts spectra from structure (ACD/NMR Predictors) and popular advanced processing, interpretation, and databasing application (ACD/NMR Workbook Suite) will also be available to JEOL customers at an incremental cost.
Is New 90 Day High Low • Sep 18New 90-day high: €27.80The company is up 10.0% from its price of €25.20 on 19 June 2020. The German market is up 6.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Medical Equipment industry, which is down 4.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €4.65 per share.
お知らせ • Jun 17JEOL Ltd. to Report Q1, 2021 Results on Aug 14, 2020JEOL Ltd. announced that they will report Q1, 2021 results on Aug 14, 2020